CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook
Consolidated revenue of $54.5M beat the consensus the company cited, but DefenCath pricing, a $3.1M adjusted EBITDA and suspended 2027 guidance leave Heron and REZZAYO carrying the story.
The quarter in numbers
CorMedix reported third-quarter 2026 consolidated revenue, defined as total revenue and grant income, of $54.5 million. The company said this was above street consensus of $51.2 million. The prior-year comparison is stark: total revenue in the third quarter of 2025 was $104.3 million.
The company recorded a net loss of $14.7 million, or $(0.19) per basic and diluted share. A year earlier it reported net income of $108.6 million, or $1.42 basic and $1.26 diluted. Adjusted EBITDA, a non-GAAP measure, was $3.1 million, against $71.9 million in the third quarter of 2025.
Two items distort the year-on-year bottom line. The 2026 loss included $11.5 million of non-cash expense from remeasuring contingent consideration tied to the Melinta acquisition. The 2025 profit included a one-time $59.7 million tax benefit from realizing deferred tax assets.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- CorMedix Inc.: quarterly results release (SEC filing) SEC EDGAR · 12 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
Iambic's Q3: AI-platform deals double revenue, but the clinic drives the burn
Collaboration revenue rose to $11.4M and pro forma cash reached about $455M after the IPO, while R&D and G&A spending climbed as Iambic moves three oncology assets toward and into the clinic.
Alumis posts narrower Q3 loss as NDA nears, but a lupus miss narrows envudeucitinib's path
Lower R&D cut the quarterly net loss to $94.9M, with a psoriasis NDA still due in 4Q 2026 and cash guided into 4Q 2027, while the LUMUS Phase 2b missed in the overall population.
Ionis lowers TRYNGOLZA outlook to ~$50M as DAWNZERA and partners carry Q3
Ionis reaffirmed total revenue, operating loss and cash guidance, but cut 2026 TRYNGOLZA sales to about $50 million from $100-110 million as its first large-indication launch ramps more slowly.